Group items matching

in title, tags, annotations or url

AstraZeneca on Wednesday (April 5) said a combination of its cancer drugs Imfinzi and Lynparza met the main goal in a late-stage trial in patients with advanced ovarian cancer. The drugmaker said treatment with a combination of those drugs, along with chemotherapy and bevacizumab - the existing standard of care - improved progression-free survival in newly diagnosed patients with advanced ovarian cancer without certain mutations. Lynparza is jointly developed with U.S.-based Merck & Co as a treatment for breast cancer in early stage with certain mutations. Imfinzi alone, along with chemotherapy and bevacizumab, did not reach statistical significance in its interim analysis, the drugmaker added. Philipp Harter, director, Department of Gynaecology and Gynaecologic Oncology, Evangelische Kliniken Essen-Mitte, Germany and principal investigator for the trial, said: "DUO-O showcases the power of academia and industry collaboration in advancing new treatment combinations for patients with ovarian cancer. I'm grateful for the academic cooperative study groups and patients around the world that made this trial possible and look forward to sharing the results with the clinical community." Susan Galbraith, executive vice president, Oncology R&D, AstraZeneca, said: "While there has been significant progress for patients with advanced ovarian cancer, an unmet need still remains. These data from the DUO-O trial provide encouraging evidence for this this Lynparza and Imfinzi combination in patients without tumour BRCA mutations and reinforce our continued commitment to finding new treatment approaches for these patients. It will be important to understand the key secondary endpoints as well as data for relevant subgroups."

The Medicines and Healthcare products Regulatory Agency (MHRA) has advised 'no one should stop taking valproate without advice from their healthcare professional.' The latest data on the use of valproate in England revealed that in the last 6 months the number of pregnant women prescribed valproate in a 6-month period has fallen from 68 women in April to September 2018, to 17 women in October 2021 to March 2022. In light of concerns that the current regulatory requirements for safe use are not being consistently followed, the MHRA conducted a review of the available data and asked for advice from the independent Commission on Human Medicines (CHM). "The CHM has advised that no one under the age of 55 should be initiated on valproate unless two specialists independently consider and document that there is no other effective or tolerated treatment," said MHRA. "Where possible, existing patients should be switched to another treatment unless two specialists independently consider and document that there is no other effective or tolerated treatment or the risks do not apply."

Product packaging affects the effectiveness of pharmaceuticals to a great extent. This is why pharmaceutical companies ensure they choose appropriate packaging for drug products. Drug packaging is not always an easy job. However, the tips in this article will help you select the proper pharmaceutical packaging for drug products without stress. What Does Pharmaceutical Packaging Entail? Pharmaceutical packaging involves using packaging containers with safety closures such as a lidding film to hold pharmaceutical products. This is done to keep them safe and effective. The most commonly used packaging materials in the pharmaceutical industry are metals, glass, and plastics. These materials are used for different reasons and different products. In short, a pharmacist considers several factors regarding a product and its target audience before choosing a packaging material for pharmaceutical formation. Why Appropriate Packaging Matters Many benefits come with appropriate pharmaceutical packaging. These benefits make it essential to package drug products in the best ways possible. When pharmaceutical items are properly packed, they can reach patients for a safe prescription. As a result, the drug stands a higher chance of achieving its prescription purpose. More so, properly packaged drug products are safer to consume and can be trusted.

The Pharmacists' Defence Association (PDA) has undertaken an additional survey of pharmacists employed in the NHS, before deciding to hold their first-ever ballot for industrial action. The PDA has more than 7,000 NHS-employed pharmacists in membership and the union is actively considering balloting those members regarding strike action. The association said: "The experience of some other unions has shown that the government's restrictive rules, designed to make it difficult for working people to lawfully take industrial action, means trade unions should test members' strength of feeling before balloting." "Trade unions are not only forced to rely upon postal ballots, but for lawful industrial action to be taken, the result must also meet three tests- at least 50% of eligible voters must vote; at least 40% of eligible voters must vote 'yes' and a majority of votes must be for 'yes'." The association is asking members in England, Northern Ireland and, Wales to show if their collective wish, insignificant enough strength, is for strike action. PDA has emailed the survey to all its members in the NHS in the three nations and will close on Tuesday 3 January.

Chiesi Farmaceutici, the international, research-focused biopharmaceuticals and healthcare group has acquired Amryt Pharma, a global biopharmaceutical company dedicated to developing novel treatments for rare diseases. More than 300 million people worldwide are affected by rare diseases, including those who are living with ultra-rare metabolic and dermatologic conditions who still have no approved treatment. The acquisition reinforces Chiesi's commitment to deliver innovative treatments to patients with highly unmet medical needs. As a benefit corporation and a B Corp, Chiesi strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. Chiesi's Head of Chiesi Global Rare diseases Giacomo Chiesi commented: "We are excited to add the Amryt family to our company in this acquisition that demonstrates our commitment to rare diseases and aligns with our growth strategy through partnerships beyond internal research and development." Chiesi's new CEO Giuseppe Accogli said: "By joining forces and expertise we will be able to grow our capabilities and further strengthen our position to provide a positive impact on patients living with rare diseases." With regard to the financing of the deal, cash consideration has been partially financed through a EUR 700m syndicated loan led by BNP Paribas and Crédit Agricole as Global Coordinators and ESG Structuring Banks, acting alongside BPER and Deutsche Bank as Mandated Lead Arrangers. Crédit Agricole is Loan Agent too. Lenders have been advised by Clifford Chance, while Baker and McKenzie has assisted Chiesi Farmaceutici.

In recent years, there has been an increased focus on the importance of health. People are looking for ways to improve their health and live a longer, more productive life. There are many different places that people can go to work on their health, but some are better than others. Here is a list of the top six places to work on your health. 1) MEDICAL SPA A medical spa is a place where people can go to improve their health. medical spas offer a variety of services, including skin care, laser hair removal, and body contouring. They also offer a variety of medical treatments, such as laser surgery and Botox injections. Medical spas offer a number of benefits to their patients. First, they offer a wide variety of services that can help people improve their health. Second, they offer a number of medical treatments that can help people address specific health concerns. Third, they offer a relaxing environment where people can come to improve their health and wellbeing. No matter if you're looking for a medical spa in Alexandria, VA, New York, or any other state, they can be a great place to work on your health. Plus, if you're looking for a place to get health insurance, they can also help you with that.

Thanks for sharing this! I started monitoring my health only when it became necessary. I am very overweight. I think buy wegovy online ( https://www.canadadrugsdirect.com/products/wegovy ) on the recommendation of a doctor. Also, I have already signed up to the gym for individual classes and also for fitness. I started to eat properly and am constantly looking for good new recipes that I can repeat at home

The British Generic Manufacturers Association has backed the UK government's proposed changes to the Statutory Scheme for branded medicines, which includes a 'Life Cycle Adjustment' (LCA) mechanism to permit a lower rebate rate for medicines sold in competitive markets. The association underscored the necessity for crucial amendments to forestall unintended consequences and ensure a practical alignment with market operations. A precisely tailored approach is crucial in ensuring sustainability and growth in this sector, the BGMA said in a statement on Oct. 11. The Department of Health and Social Care is currently working on the successor to the 2019 voluntary scheme for branded medicines and pricing access (VPAS) agreement, slated to end in 2023. Negotiations for this successor, scheduled to begin on January 1, 2024, are already underway. "We are pleased that the Statutory Scheme consultation recognises that branded generic and biosimilar medicines are subject to different market dynamics and competitive pressures," said Mark Samuels, Chief Executive of BGMA. "As such, a one-size-fits-all approach across all branded products is not suitable for the next five years. It is crucial to adopt a precisely tailored approach to this sector, ensuring both sustainability and growth."

Modulator therapies, manufactured by Vertex Pharmaceuticals (VRTX.O), may no longer be available for new cystic fibrosis (CF) patients in the UK. A draft guidance recently published by the National Institute for Health and Care Excellence (NICE) stated that it would not recommend the use of Kaftrio, Symkevi and Orkambi on new CF patients. Kaftrio and Symkevi are currently recommended for the treatment of cystic fibrosis in patients aged 6 years and older, while Orkambi is used for patients aged 1 and older. The NICE draft guidance highlighted medicine costs and the strain on resources and finances faced by the National Health Service (NHS) as reasons for removing these drugs.

As the countdown to the next UK election begins, the King's Fund has identified three priorities to improve public health. The national action would be taken by the future government to fix the "NHS and social care" in the country. The health policy think tank said it would prioritise "improving access to out-of-hospital care", making "careers in health and social care" more attractive and tackling the biggest risk factors affecting people's health. It highlighted that workforce crisis is one of the biggest challenges faced by the National Health Service (NHS) and social care services in England while citing "years of poor planning and fragmented responsibilities" as the reason for widespread staff shortages. As per the King's Fund's data, there were more than 125,000 vacancies across the NHS workforce in England in October 2023, not including primary care vacancies such as GPs, and 152,000 vacant posts in the adult social care workforce.

Nexium Control, the UK's number one selling heartburn product for 24-hour protection1, has commissioned research to explore consumer attitudes to heartburn awareness of the different products on the market in Great Britain and Ireland (1,500 UK and 500 IE respondents). The research found that 53% of respondents usually opt for short-acting treatments to heartburn2, despite longer-acting products being able to provide relief over a 24-hour period. The research from Nexium Control revealed that 54% of people surveyed wished there was a product that managed symptoms for longer3, with 55% of respondents agreeing that short-acting treatments only last a maximum of five hours4. To help their patients understand there are longer-acting options available, pharmacists can provide information and guidance on treatments, such as proton pump inhibitors like Nexium Control. Shorter-acting products, which shoppers often reach for, work by either neutralising the acid already in the stomach or by forming a layer that floats to the top of the stomach, stopping acid rising into the food pipe. Double action treatments which utilise both methods are also available. Containing esomeprazole, Nexium Control reduces the production of stomach acid for up to 24-hour protection with just one pill, treating the cause and symptoms of heartburn - allowing time for the oesophagus to recover from the acid irritation.

The Medicines and Healthcare products Regulatory Agency (MHRA) on Wednesday (9 January) announced that the novel type 2 oral polio vaccine (nOPV2) has been quality-assured (prequalified) by the World Health Organization (WHO). Developed by a team including scientists from the MHRA, nOPV2 is considered a safer polio vaccine that helps to protect children from the disabling and life-threatening disease and lower the risk of vaccine-derived outbreaks. The vaccine received WHO Emergency Use Listing three years ago, and since then 950 million doses have been delivered worldwide. The UN health agency's decision to add it to the list of prequalified vaccines is based on the analysis of outcomes in vaccinated populations that has confirmed strong safety profile and effectiveness.

The UK government's community diagnostic centre programme, which was first launch in July 2021, is helping cut waiting lists, and speed up diagnoses and treatments for NHS patients. As of November 2023, a total of 6.1 million vital checks have been carried out at community diagnostic centres (CDCs) across England, according to a joint statement released by the Department of Health and Social Care (DHSC) and NHS England. Under the £2.3 billion programme, 141 CDCs have been opened across the country in a variety of settings including shopping centres, university campuses and football stadiums, offering patients a wide range of diagnostic tests closer to home. The government has set a target to open 160 CDCs by March 2025, with many expected to open ahead of schedule.

The Pharmacist's Defence Association (PDA) has raised concerns over the adoption of Digital Clinical Excellence (DiCE) guidelines for online prescribing of GLP-1 receptor agonists for weight management in adults. This follows a clash with expert recommendations commissioned by the General Pharmaceutical Council (GPhC) as the PDA "believes the final guidance conflicts with the expert opinion underpins the GPhC's prosecution strategy towards pharmacist prescribers under investigation." In a recent statement, the PDA highlighted the discrepancy between DiCE's guidance and the expert report employed by the GPhC to prosecute pharmacist prescribers using a questionnaire-based consultation model. This conflict has prompted the PDA to withhold its endorsement of the DiCE guidance as it differs from an expert report commissioned by the GPhC. The PDA's reservations stem from the inherent risks associated with questionnaire-based prescribing.

In a significant leap forward in the fight against HIV, the Medicines and Healthcare products Regulatory Agency (MHRA) has given the green light to two groundbreaking formulations of cabotegravir. Apretude 30 mg film-coated tablets and Apretude 600 mg prolonged-release suspension for injection are now authorized for preventing sexually transmitted HIV-1 infection in adults and adolescents weighing at least 35kg at increased risk. This approval marks a pivotal moment in HIV (human immunodeficiency virus) prevention, offering an alternative to existing standard pre-exposure prophylaxis or PrEP treatments. HIV, a virus notorious for compromising the immune system, has long been a global health concern. Cabotegravir, a member of the integrase inhibitor group, works by blocking a key enzyme necessary for the replication of HIV-1, thereby reducing the virus's ability to spread.

The latest formulation of XGEVA (denosumab) is now available to patients in the UK, offering a more convenient treatment option for bone metastasis. It is the first product to be authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) via the new International Recognition Procedure (IRP). Denosumab (XGEVA) is used to prevent serious bone-related complications resulting from bone metastasis in adults and to treat giant cell tumour of bone in both adults and adolescents. The medicine was authorised on 29 February 2024 as a 120 mg solution for injection in a prefilled syringe. In contrast to the current vial presentation, this simplifies the administration process, reducing the volume of liquid injected and lowering the risk of dosing errors. The product was authorised in 30 days by the MHRA, thanks to the new IRP that facilitated a rapid approval process.

Reacting to recommendations from a UK-first independent review, the Department of Health and Social Care (DHSC) has outlined action to tackle potential bias in the design and use of medical devices. Professor Dame Margaret Whitehead, professor of public health at the University of Liverpool, was appointed to lead the review, which focused on three areas - optical devices such as pulse oximeters, AI-enabled devices, and polygenic risk scores (PRS) in genomics. The DHSC commissioned the medical devices review after concerns were raised that pulse oximeters - widely used during the COVID-19 pandemic to monitor blood oxygen levels - were not as accurate for patients with darker skin tones. There were worries that this could cause delays in treatment if dangerously low oxygen levels in such patients were missed. However, no evidence was found from NHS studies indicating that this differing performance had an impact on patient care. Accepting the report's conclusions, the DHSC has committed to several actions, such as ensuring the safe use of pulse oximeter devices across a range of skin tones within the NHS and eliminating racial bias from data sets employed in clinical studies.

The UK Health Security Agency (UKHSA) and The Pirbright Institute have launched a new collaboration to develop vaccines against henipavirus, a genus of viruses that includes Nipah virus. Funded by the Medical Research Council, this research aims to develop a vaccine that provides cross protection against the whole genus, addressing the threat of outbreaks from new or emerging henipaviruses and strengthening epidemic preparedness. Scientists at UKHSA will evaluate the protective efficacy of vaccines developed by The Pirbright Institute by using use a model of Nipah virus disease, which mimics the infection in humans. Professor Isabel Oliver, chief scientific officer at UKHSA, stated that the study would improve understanding of henipaviruses and enhance efforts to protect health from this "current and future global health threat." "The work will also make a vital contribution to the 100 Days Mission - an important initiative to make sure the world is better prepared for the next pandemic by accelerating the development of diagnostics, therapeutics and vaccines," he added.

The number of people living to be 100 or more increased by 3.7 per cent in England and Wales in 2022, compared to the previous year, according to new figures from the Office for National Statistics (ONS). ONS data also revealed that the number of centenarians in the UK has more than doubled in the last two decades. Wales has more centenarians (27 people per 100,000 aged 100 or over) than England (25 people per 100,000). It's good news that more people are living into their second century, but it also means that we may need to rethink our health plans for a longer future, a leading testing expert has suggested.

The severity of the ADHD medication shortage in the UK has been exposed as former Hollywood extra Lee Cato revealed that he was forced to quit his job but hasn't been able to access his medicine. A resident of Berkhamsted, Hertfordshire, Lee had worked as a film extra in big movies like 'Thor' and 'Edge of Tomorrow'. The 48-year-old told Mirror that he has been taking Concerta for years to manage ADHD symptoms, but he hasn't been able to get the drug or any alternatives for over a month. He said that he first experienced shortages of the medicine in December 2023 but was initially able to take Delmosart, which he took to maintain focus despite experiencing its side effects such as headaches, nausea, tooth erosion, and a dry mouth. But now, he can't get access to any of these ADHD drugs as "they're completely out-of-stock and it's been over a month now." His chemist also tried to get hold of his medication but failed.

What initially began as two close friends taking a leisurely walk to escape their everyday routine has evolved into a meaningful endeavour to support the fight against cancer. Jamie Sparrow, Senior Vice President - Commercial, EMENA at Accord Healthcare, and Jamie Durbidge, Owner & Managing Director of Perennial Pharma, will be undertaking a 5-day walking challenge to support The Luke Hart Foundation in raising funds for Cancer Research UK. The two Jamies have been friends for more than 15 years and worked together at Mylan, now Viatris, where Jamie S served as Managing Director, while Jamie D held the position of Sales Director for some years. During the COVID pandemic when everybody was stuck at home, the two friends, both early risers, used to spend hours in the mornings walking and talking over the phone, about anything and everything - work, life, family, the Pharmaceutical Industry, politics, sport, and about challenges that people were having during the lockdown. After continuing this routine for several months, they eventually planned to transform their daily ritual into a "walking and talking" trip to reconnect, catch up on things, and enjoy some time together and with friends who wanted to join them.